经尿道超脉冲双极等离子汽化电切术治疗前列腺增生(附236例报告)

于新路; 孟强; 安康; 祁连友; 李国利; 曹丽佳

经尿道超脉冲双极等离子汽化电切术治疗前列腺增生(附236例报告)

- 1. 武警辽宁省总队医院泌尿外科(沈阳, 110034);
- 2. 辽宁省人民医院泌尿外科

详细信息

通讯作者: 于新路,E-mail:yuxinlu1008@163.com

中图分类号: R697

收稿日期: 2011-07-28

Transturethral Super-pulse Plasmakingetic electrovaporization therapy for patients with benign prostate hyperplasia (Report of 236 cases)

- 1. Department of Urology, Liaoning Provincial Cops Hospital, Chinese People's Armed Police, Shenyang, 110034, China;
- 2. Department of Urology, Liaoning Provincial People's Hospital

More Information

Corresponding author: YU Xinlu, E-mail: yuxinlu1008@163.com

Received Date: 28 July 2011

摘要

摘要: 目的：讨论超脉冲双极等离子汽化电切术（SP-PK +TUEVP）治疗BPH的疗效和安全性。方法：总结2008年5月~2011年3月采用SP超脉冲等离子双极气化电切术（PKSP）治疗BPH患者236例的临床资料，观察术中情况、术后并发症及疗效。结果：236例均手术成功，手术时间36~110 min，平均48 min，切除前列腺组织28~129 g。术中失血60~100 ml，平均70 ml。术后3个月236例中最大尿流率术后平均18.5 ml/s；IPSS评分降至（6.7±1.4）分；QOL评分降至（1.8±0.4）分。结论：PKSP治疗BPH并发症少，临床应用安全、有效。
- 前列腺增生 /
- 超脉冲双极等离子体电切术 /
- 疗效
Abstract: Objective: To evaluate the safety and efficacy of transturethral Super-pulse bipolar Plasmakingetic electrovaporization of prostate(SP-PK+TUEVP)for the treatment of patients with benign prostate hyperplasia.Methods: clinical experiences of transurethral plasmakinetic electrovaporization(PKSP)treatment for 236 cases of benign prostate hyperplasia during May2008 to Mar 2011 were analyzed. Information form operation and postoperative complications and curative effect were observed.Results: 236 patients underwent SP-PK+TUEVP safely.The operating time was from 36 to 110 minutes,averaged 48 min. Specimen weight was from 28 to 129 g. The mean blood loss was 70 ml(60-100 ml). With follow up of 3-6 months,all patients had fluent urination. Average Maximal flow mate(Q_max) was 18.5ml/s.International Prostate Symptom Scores(IPSS)were decreased to(6.7±1.4).Quality of Life(QOL) decreased to (1.8±0.4).Conclusions: With high effectiveness,safety,and less complications, PKSP is a safe and effective therapy for patients with benign prostate hyperplasia.
- prostate hyperplasia /
- Super-pulse bipolar plasmakinefic electrovaporization of prostate /
- curative effect

HTML全文

参考文献(6)

[1]	ROEHRBORN C G, MCCONNELL J, BONILLA J,et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study[J]. J Urol, 2000, 163(1):13-20.
[2]	MCCONNELL J D,BARRY M J, BRUSKEWITZ R C. Benign prostatic hyperplasia:diagnosis and treatment. Agency for Health Care Policy and Research[J]. Clin Pract Guidel Quick Ref Guide Clin,1994,8:1-17.
[3]	VARKARAKIS J, BARTSCH G,HORNINGER W. Long-term morbidity and mortality of transurethral prostatectomy:a 10-year follow-up[J]. Prostate,2004,58(3):248-251.
[4]	周兴,刘春晓,郑少渡,等.经尿道双极汽化技术治疗高危前列腺增生症[J].中国内镜杂志,2003,9:58-59.
[5]	BHANSALI M,PATANKAR S, DOBHADA S,et al. Management of large (>60 g) prostate gland:PlasmaKinetic Superpulse (bipolar) versus conventional (monopolar) transurethral resection of the prostate[J]. J Endourol,2009,23(1):141-145.
[6]	PATANKAR S, JAMKAR A,DOBHADA S,et al. PlasmaKinetic Superpulsetransurethral resection versus conventional transurethral resection of prostate[J]. J Endourol,2006,20(3):215-2159.